Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 12 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 von Hippel-Lindau Disease 2 Pheochromocytoma 1 Paraganglioma 1 Kidney Neoplasms 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Cisplatin 11 Specimen Handling 9 Magnetic Resonance Spectroscopy 9 pembrolizumab 6 durvalumab 6 Platinum 6 1,2-diaminocyclohexaneplatinum II citrate 6 cemiplimab 5 Carboplatin 5 Radiation 4 Cetuximab 4 Biopsy 4 poly ICLC 3 Radiotherapy, Intensity-Modulated 3 Radiotherapy 3 Pemetrexed 3 Paclitaxel 3 Nivolumab 3 Docetaxel 3 (225)Ac-DOTA-c(RGDyK) 3 ipatasertib 2 cabozantinib 2 atezolizumab 2 Oxaliplatin 2 Ipilimumab 2 Immunoglobulin G 2 Fluorouracil 2 Disulfides 2 Capecitabine 2 ALT-803 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × belzutifan × 30 days × Clear all

NCT07227402 2026-06-04

LITESPARK-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡